Clinical Case Reports (Mar 2022)
Intralesional bleomycin for treatment of a recalcitrant wart in an immunocompromised patient: A safe, effective, and underutilized therapy
Abstract
Abstract Injectable bleomycin is infrequently used for recalcitrant warts despite its efficacy, acceptable safety profile, and high patient satisfaction compared with other treatment modalities. We present an immunocompromised patient with a large recalcitrant wart successfully treated with intralesional bleomycin to provide greater clinical exposure, training, and practice with intralesional bleomycin.
Keywords